MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
9.40
-0.01
-0.11%
After Hours: 9.25 -0.15 -1.58% 17:03 04/02 EDT
OPEN
9.21
PREV CLOSE
9.41
HIGH
9.44
LOW
9.15
VOLUME
587.49K
TURNOVER
--
52 WEEK HIGH
13.16
52 WEEK LOW
6.19
MARKET CAP
551.89M
P/E (TTM)
6.94
1D
5D
1M
3M
1Y
5Y
1D
Zevra Therapeutics Earnings Call Signals Profitable Turn
TipRanks · 2d ago
Weekly Report: what happened at ZVRA last week (0323-0327)?
Weekly Report · 5d ago
Weekly Report: what happened at ZVRA last week (0316-0320)?
Weekly Report · 03/23 09:39
Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone
Simply Wall St · 03/21 13:09
Zevra Therapeutics grants CFO Justin Renz 300,000-share option at USD 9.55 exercise price
Reuters · 03/20 20:30
ZEVRA THERAPEUTICS REPORTS INDUCEMENT GRANT TO NEW CHIEF FINANCIAL OFFICER UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/20 20:30
Zevra Therapeutics CFO Justin A. Renz Files Initial Beneficial Ownership Statement
Reuters · 03/19 20:15
Zevra Pharmaceuticals: SDX Monetization, Debt Elimination, and Miplyffa Ramp Support Buy Rating
TipRanks · 03/16 22:05
More
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.